OSLO, Feb. 18, 2021 /PRNewswire/ -- Targovax ASA, a
clinical stage immuno-oncology company developing immune activators
to target hard-to-treat solid tumors, will host a virtual Capital
Markets Day for investors, analysts and journalists today at
2:30 PM CET. The Capital Markets Day
will feature presentations from executive management and Alexander
Shousthari, Clinical Director Melanoma Services at Memorial Sloan
Kettering Cancer Center, and will be webcast live and accessible
at https://www.targovax.com/en/capital-markets-day-2021/
Based on the strong clinical data that are now generated
on ONCOS-102, Targovax has a solid fundament to move into late
stage clinical development. We also have a broader pipeline of
preclinical assets that could create a broader horizon of
opportunities in the future. The Capital Markets day will feature
presentations updating the market on these aspects.
The agenda will be as follows:
Agenda &
speakers
|
2:30-2:40
PM
|
Welcome
|
Øystein Soug, CEO,
Targovax
|
2:40-3:25
PM
|
Anti-PD1 refractory
melanoma
|
Alexander N.
Shoushtari, MD
|
3:25-3:45
PM
|
ONCOS-102 development
program
|
Magnus Jäderberg, MD,
CMO, Targovax
|
5-minute
break
|
3:50-4:05
PM
|
Immune
activation
|
Victor Levitsky, PhD
CSO, Targovax
|
4:05-4:15
PM
|
Preclinical pipeline
update
|
Victor Levitsky, PhD,
CSO, Targovax
|
4:15-4:25
PM
|
4Q update
|
Torbjørn Furuseth,
MD, CFO, Targovax
|
4:25 PM
|
Closing
remarks
|
Øystein Soug, CEO,
Targovax
|
The presentations will be made available on the company's
website after
The presentations will be made available on the company's
website after the end of the meeting. Questions can be submitted
through the webcast throughout the event.
Biography:
Dr. Alexander Shoushtari
is a renowned expert in melanoma, with a research focus on
checkpoint refractory melanomas. He is a Clinical Director and
Assistant attending physician at Melanoma Services, Dept of
Medicine, Memorial Sloan Kettering Cancer Center. Dr. Alexander Shoushtari is Principal investigator
of several immunotherapy trials, including the ONCOS-102 phase I
trial in CPI refractory advanced melanoma.
For further information, please contact:
Renate Birkeli
Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas
Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton
Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/reminder--invitation-to-targovax-s-capital-markets-day-18-february-2021,c3289265